RESUMEN
Psoriasis is a chronic inflammatory systemic disease with a prevalence of 2-3%. Overwhelming evidence show an epidemiological association between psoriasis, cardiovascular disease and atherosclerosis. Cardiovascular disease is the most frequent cause of death in patients with severe psoriasis. Several cardiovascular disease classical risk factors are also increased in psoriasis but the psoriasis-associated risk persists after adjusting for other risk factors.Investigation has focused on finding explanations for these epidemiological data. Several studies have demonstrated significant lipid metabolism and HDL composition and function alterations in psoriatic patients. Altered HDL function is clearly one of the mechanisms involved, as these particles are of the utmost importance in atherosclerosis defense. Recent data indicate that biologic therapy can reverse both structural and functional HDL alterations in psoriasis, reinforcing their therapeutic potential.
Asunto(s)
Enfermedades Cardiovasculares/inducido químicamente , Metabolismo de los Lípidos , Lipoproteínas HDL/efectos adversos , Psoriasis/complicaciones , Aterosclerosis/inducido químicamente , Aterosclerosis/epidemiología , Enfermedades Cardiovasculares/epidemiología , Humanos , Psoriasis/epidemiología , Factores de RiesgoRESUMEN
INTRODUCTION: Neurocutaneous syndromes (NCS) are a heterogeneous group of conditions with multiorgan involvement and diverse manifestations, evolving throughout life with significant morbidity. A multidisciplinary approach to NCS patients has been advocated, although a specific model is not yet established. The aim of this study was 1) to describe the organization of the recently created Multidisciplinary Outpatient Clinic of Neurocutaneous Diseases (MOCND) at a Portuguese pediatric tertiary hospital; 2) to share our institutional experience focusing on the most common conditions, neurofibromatosis type 1 (NF1) and tuberous sclerosis complex (TSC); 3) to analyze the advantages of a multidisciplinary center and approach in NCS. METHODS: Retrospective analysis of 281 patients enrolled in the MOCND over the first five years of activity (October 2016 to December 2021), reviewing genetics, family history, clinical features, complications, and therapeutic strategies for NF1 and TSC. RESULTS: The clinic works weekly with a core team of pediatricians and pediatric neurologists supported by other specialties as needed. Of the 281 patients enrolled, 224 (79.7%) had identifiable syndromes such as NF1 (n = 105), TSC (n = 35), hypomelanosis of Ito (n = 11), Sturge-Weber syndrome (n = 5), and others. In NF1 patients, 41.0% had a positive family history, all manifested café-au-lait macules, 38.1% neurofibromas with 45.0% being large plexiform neurofibromas. Sixteen were under treatment with selumetinib. Genetic testing was performed in 82.9% of TSC patients with pathogenic variants found in TSC2 gene in 72.4% patients (82.7% if considered contiguous gene syndrome). Family history was positive in 31.4%. All TSC patients presented hypomelanotic macules and fulfilled diagnostic criteria. Fourteen patients were being treated with mTOR inhibitors. CONCLUSION: Offering a systematic and multidisciplinary approach to NCS patients enables timely diagnosis, promotes a structured follow-up, and encourages discussion to outline management plans for optimal care to every patient, with significant impact on the quality of life of patients and families.
Asunto(s)
Síndromes Neurocutáneos , Neurofibromatosis 1 , Humanos , Niño , Portugal , Síndromes Neurocutáneos/diagnóstico , Síndromes Neurocutáneos/terapia , Calidad de Vida , Estudios Retrospectivos , Centros de Atención Terciaria , Instituciones de Atención Ambulatoria , Neurofibromatosis 1/terapiaRESUMEN
OBJECTIVES: Generalized pustular psoriasis (GPP) is a rare, life-threatening skin inflammatory disorder. This study aimed to describe the disease course, treatment strategies, and healthcare utilization among patients with GPP in Portugal. METHODS: This multicentric, observational, retrospective study included consecutive adult patients with GPP undergoing a dermatology evaluation in different reporting institutions by experienced dermatologists between 2002 and 2023. RESULTS: A total of 59 patients were assessed. Most of the cohort had a previous history of plaque psoriasis (71%) and 83% presented at least one comorbidity. At the initial encounter, 64% of the cohort needed hospitalization. Systemic involvement was common, including fever (37%), and elevated white blood cell count and erythrocyte sedimentation rate/C-reactive protein (49%). Nearly, 73% of patients initiated systemic drugs, and 70% had to discontinue the first treatment. During the study, 98% of patients experienced at least one flare. At the last visit, 3.4% of patients had died, and 71.2% exhibited signs of active disease despite undergoing treatment. CONCLUSIONS: Our study demonstrates that GPP is a chronic, debilitating condition associated with systemic involvement, frequent flares, and hospitalizations, despite receiving multiple systemic treatments. Improved disease awareness and new treatments are needed to improve patient care and decrease the burden of the disease.
Asunto(s)
Costo de Enfermedad , Hospitalización , Psoriasis , Humanos , Psoriasis/terapia , Psoriasis/patología , Psoriasis/tratamiento farmacológico , Psoriasis/diagnóstico , Estudios Retrospectivos , Portugal/epidemiología , Masculino , Femenino , Persona de Mediana Edad , Adulto , Hospitalización/estadística & datos numéricos , Anciano , Comorbilidad , Fármacos Dermatológicos/uso terapéutico , Aceptación de la Atención de Salud/estadística & datos numéricos , Índice de Severidad de la EnfermedadRESUMEN
INTRODUCTION: Psoriasis is a common, chronic, and inflammatory skin disorder with a high personal, social and economic burden and important implications for healthcare systems. The aim of this study was to provide an epidemiological characterization of individuals with psoriasis in Portugal. MATERIAL AND METHODS: A large observational, cross-sectional, nationwide, population-based survey study developed by the Portuguese Psoriasis Group of the Portuguese Society of Dermatology and Venereology (GPP-SPDV). A structured questionnaire was designed and applied by experienced interviewers to a random, representative sample of Portuguese individuals with psoriasis and/or psoriatic arthritis. Patients were considered to have psoriasis if they replied positively to one of the following questions: "Does any physician have ever diagnosed you with psoriasis?" or "Do you have a skin disorder characterized by scaling, reddish skin lesions located in the elbows/knees/scalp?". RESULTS: A total of 6381 individuals were interviewed, of which 283 met the criteria for psoriasis, corresponding to a prevalence rate of 4.4% (95% CI 3.95 - 4.98). Out of the participants that met psoriasis criteria, 24% had suggestive signs/symptoms but did not have a clinical diagnosis established and were not being monitored by a physician. Although more than 70% of participants had active disease (scaling, erythema, or pruritus) and one third had joint symptoms, only 12% were on systemic treatment. Fifty percent of participants with psoriasis (n = 139) had relevant comorbidities (most frequently depression/anxiety and cardiometabolic diseases). Sixteen percent of participants with psoriasis (n = 46) reported that psoriasis interfered with their daily activities (median impact of 5 in a 0 - 10 scale) and 12% mentioned the disease had an impact in their sexual life (median impact of 5 in a 0 - 10 scale). CONCLUSION: The results of this study suggest that the prevalence rate of psoriasis is likely to be high in Portugal, and several gaps exist at different levels of healthcare delivery to these patients, from diagnosis to treatment. This study provides important data for the future planning of interventions targeting the improvement of psoriasis care in Portugal.
Asunto(s)
Artritis Psoriásica , Psoriasis , Humanos , Portugal/epidemiología , Estudios Transversales , Psoriasis/epidemiología , Psoriasis/tratamiento farmacológico , Artritis Psoriásica/epidemiología , Artritis Psoriásica/diagnóstico , Piel/patologíaRESUMEN
Atopic dermatitis is a highly prevalent chronic, immune-mediated inflammatory skin disease with a significant burden on patients, families and healthcare systems. This article presents recommendations developed by the Atopic Dermatitis Group of the Portuguese Society of Dermatology and Venereology addressing several clinical questions that arise in the management and care of moderate-to-severe atopic dermatitis with biologic agents and Janus kinase (JAK) inhibitors based on the available evidence. The recommendations were generated after a thorough evaluation of existing guidelines on the treatment of atopic dermatitis, publications concerning new biologics and JAK inhibitors not yet incorporated into existing guidelines, and expert-based recommendations. It also includes considerations on atopic dermatitis severity, indications for initiating biologic agents and JAK inhibitors, parameters to be considered in the treatment choice, in particular treatment goals, and recommendations for the use, screening and monitoring of these therapies.
RESUMEN
BACKGROUND: The COVID-19 pandemic introduced new challenges in several dimensions in healthcare services. Herein, we describe the real-life strategies and therapeutic options adopted by dermatologists regarding their patients with psoriasis being treated with or with an indication for systemic therapy during the first COVID-19 lockdown period in Portugal. METHODS: The study involves a web-based survey on the clinical management of systemic therapy for psoriasis during the COVID-19 pandemic administered to Portuguese dermatologists. The survey consisted of 55 questions (4 open-ended questions; 51 closed-ended questions), grouped into 6 sections. RESULTS: A total of 60 dermatologists voluntarily participated in this survey. Nearly 63% of the participants opted for suspending biologics during the COVID-19 lockdown period and 23.3% increased the time between drug administrations. Eighty percent of the participants agreed that biologics did not change the probability of acquiring COVID-19 and 58.4% believed that these drugs decreased or did not change the severity of the disease. Approximately one-third of the participants opted not to prescribe a biological agent in patients despite clinical indication over the duration of the pandemic. Nearly 25% of the participants opted for suspending traditional immunosuppressant administration. Virtual appointments were an option for 93.3% of the participants. CONCLUSION: The COVID-19 pandemic has significantly affected the management of patients with psoriasis being treated with or with an indication for systemic therapy. Some of the decisions made during the first lockdown period were contrary to what we know today. These decisions might have had a significant impact on patients' quality of life and on future therapeutic success. An adequate interpretation and analysis of the available data will be extremely important to an insightful adaptation of the clinical practice in future confinement or restrictive scenarios.
RESUMEN
Psoriasis is a chronic inflammatory immune disorder associated with an increased risk of atherosclerosis. This increased risk is not fully understood. High-density lipoproteins (HDL) play an important role in the prevention of atherosclerosis and any factors that may hamper HDL function such as anti-HDL antibodies (aHDL) might be associated with an increased cardiovascular risk. We aimed to determine whether anti-HDL antibodies (aHDL) are present in patients with psoriasis. Sixty-seven patients with psoriasis were compared with a healthy control group. Epidemiologic and clinical data were recorded. IgG and IgM aHDL, IgG anti-apolipoprotein A-I (aApoA-I), anti-apolipoprotein E (aApoE), and anti-paraoxonase 1 (aPON1) antibodies, as well as VCAM-1, IL-6, and TNF-α were assessed by ELISA. Apolipoprotein A-I (ApoA-I) and Apolipoprotein E (ApoE) were measured by immunoturbidimetric immunoassay. Patients with psoriasis had higher titers of IgG aHDL (p < 0.001), IgG aApoA-I (p = 0.001) and aApoE antibodies (p < 0.001). IgG aHDL and aApoE titers were higher in patients with severe psoriasis (p = 0.010 and p = 0.018, respectively). Multiple regression analysis, considering all clinical and biological variables, showed that aApoE, IL-6, and aPON1 are the biological variables that best explain aHDL variability. This is the first report showing the presence of aHDL, aApoA-I, and aApoE antibodies in patients with psoriasis. These antibodies were associated with increased disease severity and may contribute to the pathogenesis of atherosclerosis in psoriasis. They may fulfill the clinical need for biomarkers of cardiovascular risk associated with psoriasis that would help to stratify patients for prevention and therapeutic approaches.
Asunto(s)
Anticuerpos/sangre , HDL-Colesterol/inmunología , Psoriasis/inmunología , Adulto , Apolipoproteínas/inmunología , Biomarcadores , Estudios de Casos y Controles , Citocinas/genética , Citocinas/metabolismo , Femenino , Humanos , Inmunoglobulina G , Masculino , Persona de Mediana Edad , Psoriasis/sangreRESUMEN
Psoriasis is a highly prevalent chronic, inflammatory multisystem disease with a considerable impact on patients' quality of life and the healthcare system. This report presents the recommendations developed by the Portuguese Psoriasis Group of the Portuguese Society of Dermatology and Venereology that address several clinical questions arising during the management and care of psoriasis with biologic therapy, based on the available evidence. The recommendations were generated following thorough evaluation of existing guidelines on the treatment of psoriasis, publications concerning new biologic treatments that have not yet been considered in existing guidelines, as well as expert-based recommendations. Considerations regarding the severity of psoriasis, indications for initiating biologic therapy, parameters to be considered in treatment choice (in particular, treatment goals), as well as recommendations for using and monitoring therapy and screening programmes are also included.
Asunto(s)
Terapia Biológica , Psoriasis/tratamiento farmacológico , Humanos , Portugal , Índice de Severidad de la EnfermedadAsunto(s)
Azetidinas , Dermatitis Atópica , Humanos , Dermatitis Atópica/diagnóstico , Dermatitis Atópica/tratamiento farmacológico , Azetidinas/efectos adversos , Purinas/efectos adversos , Pirazoles/efectos adversos , Resultado del Tratamiento , Índice de Severidad de la Enfermedad , Método Doble CiegoRESUMEN
INTRODUCTION: Some cutaneous lesions might be the first clinical manifestation of diseases with systemic involvement. This article aims to review the relevant dermatological semiology for the concerning diseases with neurological involvement in childhood. MATERIAL AND METHODS: Review of the related literature indexed to MedLine published in the last twelve years. RESULTS: The main relevant nosologic groups include the genodermatosis (namely neurocutaneous syndromes), pigmentary, vascular and endocrine disorders, congenital enzymatic deficiencies and occult spinal dysraphisms. DISCUSSION: The recognition of specific cutaneous signs is important once may enable a much earlier diagnosis.
Introdução: Algumas alterações cutâneas podem ser as primeiras manifestações clínicas de diversas entidades nosológicas com atingimento sistémico. O presente trabalho tem como objectivo rever a semiologia dermatológica relevante no contexto das doenças com envolvimento neurológico na infância. Material e Métodos: Revisão dos artigos indexados à MedLine publicados nos últimos 12 anos e com relevância para o tema. Resultados: Os principais grupos nosológicos relevantes para o tema compreendem as genodermatoses (com destaque para as síndromes neurocutâneas), as alterações da pigmentação, as doenças vasculares, as endócrinas, os défices enzimáticos congénitos e os disrafismos espinhais ocultos. Discussão: O reconhecimento da semiologia cutânea específica é importante pois pode permitir um diagnóstico muito mais precoce.
Asunto(s)
Enfermedades del Sistema Nervioso/complicaciones , Enfermedades de la Piel/etiología , Niño , Humanos , Enfermedades del Sistema Nervioso/diagnóstico , Neurofibromatosis 1/complicaciones , Trastornos de la Pigmentación/etiología , Esclerosis Tuberosa/complicaciones , Enfermedades Vasculares/complicacionesAsunto(s)
Dermatitis Atópica/tratamiento farmacológico , Factores Inmunológicos/uso terapéutico , Rituximab/uso terapéutico , Niño , Dermatitis Atópica/genética , Exones , Factores de Intercambio de Guanina Nucleótido/genética , Heterocigoto , Humanos , Síndrome de Job/diagnóstico , Síndrome de Job/genética , Masculino , MutaciónRESUMEN
During the summer, beach related skin lesions are common reasons for emergency room and dermatology office visits. The authors describe the case of a child with a painful maculopapular rash that resulted after a probable cutaneous exposure to a portuguese-man-of-war. He did not show other signs or symptoms and was discharged home on medications including analgesics, anti-histamines and topical steroids. A week later the skin lesions were completely healed. Even though most cases of marine dermatitis found in Portugal are low-severity, it is important to study the fauna and flora of each region to improve medical care.
Durante a época do Verão, as lesões cutâneas que surgem na praia são um motivo frequente de recurso aos serviços de urgência e de consulta de dermatologia. Os autores descrevem o caso de uma criança com uma lesão maculopapular dolorosa que resultou de um provável contato com uma caravela-portuguesa. Não apresentava outros sinais ou sintomas pelo que foi medicada em ambulatório com analgesia, anti-histamínico e corticoide tópico. Após uma semana de evolução constatou-se resolução completa das lesões cutâneas. Apesar da gravidade da maioria dos casos de dermatoses marítimas encontradas em Portugal ser ligeira, considera-se ser importante o estudo da fauna e da flora de cada região para adequar os cuidados terapêuticos.
Asunto(s)
Dermatitis/etiología , Hidrozoos , Animales , Niño , Humanos , MasculinoRESUMEN
INTRODUCTION: Patient satisfaction is a commonly used indicator for measuring quality in health care. In this context, patients are recognized as important and active agents in improving health services. In Portugal, progress has been made in characterizing concerns and needs of the national health system users, through the analysis of complaints and litigations. OBJECTIVE: To analyse complaints related to care in an outpatient dermatology department in a Portuguese hospital. MATERIAL AND METHODS: All complaints referring to the dermatology department and registered from 2000 to 2010 were analysed. RESULTS: During the eleven-year study period, 106 complaints were recorded, amounting to a rate of 0.4, and an increasing propensity to claim. Plaintiffs were mostly women (60.4%). The 'Administrative or Organizational' complaints were more prevalent than those pertaining to 'Healthcare Professionals' (58.5% vs. 41.5%). The former were mainly allusive to the 'Laws and Rules' of the institution,followed by claims related to 'Administrative Procedures'. All of the dissatisfaction records on the 'Healthcare Professionals' group were directed to doctors and medical acts. 'Frustrated Expectation' was the most frequent category in claims towards doctors, followed by'Behavioural' related ones. CONCLUSIONS: The rate of dermatology complaints in the studied department remains low comparatively to the national hospital average.The increase in the number of patients making claims can be attributed to higher demands and enhanced knowledge (or its absence) of their rights. These results emphasize the importance of the recent organizational improvements and highlight the doctor patient relationship. Health education might render a better management of health expectations and resources.